Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 03:52PM ET
70.50
Dollar change
+1.08
Percentage change
1.56
%
IndexS&P 500 P/E50.83 EPS (ttm)1.39 Insider Own1.03% Shs Outstand157.64M Perf Week-2.53%
Market Cap11.08B Forward P/E34.69 EPS next Y2.03 Insider Trans-0.64% Shs Float155.58M Perf Month-5.23%
Income224.12M PEG6.60 EPS next Q0.45 Inst Own100.36% Short Float3.28% Perf Quarter-9.82%
Sales1.15B P/S9.68 EPS this Y-11.53% Inst Trans1.98% Short Ratio4.73 Perf Half Y4.34%
Book/sh12.50 P/B5.64 EPS next Y15.44% ROA8.80% Short Interest5.10M Perf Year-1.56%
Cash/sh0.86 P/C81.69 EPS next 5Y7.70% ROE11.82% 52W Range51.79 - 89.91 Perf YTD-8.63%
Dividend Est.0.25 (0.36%) P/FCF49.17 EPS past 5Y16.30% ROI8.94% 52W High-21.59% Beta1.21
Dividend TTM0.32 (0.45%) Quick Ratio3.03 Sales past 5Y12.42% Gross Margin67.23% 52W Low36.13% ATR (14)2.04
Dividend Ex-DateFeb 09, 2024 Current Ratio4.37 EPS Y/Y TTM-14.72% Oper. Margin22.66% RSI (14)46.01 Volatility2.43% 3.03%
Employees3050 Debt/Eq0.28 Sales Y/Y TTM2.25% Profit Margin19.57% Recom1.40 Target Price80.32
Option/ShortYes / Yes LT Debt/Eq0.28 EPS Q/Q-44.48% Payout18.16% Rel Volume0.71 Prev Close69.42
Sales Surprise-1.78% EPS Surprise-2.96% Sales Q/Q0.37% EarningsFeb 01 BMO Avg Volume1.08M Price70.50
SMA20-3.15% SMA50-1.19% SMA200-2.78% Trades Volume748,600 Change1.56%
Date Action Analyst Rating Change Price Target Change
Feb-08-24Initiated Scotiabank Sector Outperform $80
Feb-02-24Downgrade Stifel Buy → Hold $65
Dec-07-23Initiated UBS Buy $80
Aug-28-23Initiated William Blair Outperform
Jan-10-23Upgrade Wells Fargo Underweight → Equal Weight $90
Dec-14-22Initiated Deutsche Bank Buy $100
Dec-12-22Upgrade Citigroup Neutral → Buy $81.25 → $100
Dec-07-22Initiated RBC Capital Mkts Sector Perform $89
Aug-25-22Initiated Credit Suisse Outperform $465
Apr-25-22Downgrade Wells Fargo Equal Weight → Underweight $370
Today 09:00AM
Mar-22-24 07:00AM
Mar-18-24 08:01PM
Mar-17-24 08:50AM
Mar-12-24 07:00AM
07:00PM Loading…
Mar-11-24 07:00PM
Mar-06-24 07:00AM
Feb-23-24 06:15AM
Feb-13-24 08:00AM
Feb-02-24 10:47AM
04:45AM
Feb-01-24 12:57PM
07:51AM
07:07AM
06:30AM
06:30AM Loading…
06:30AM
Jan-29-24 07:00AM
Jan-25-24 07:00AM
Jan-24-24 07:00AM
Jan-21-24 01:16PM
Jan-16-24 07:00AM
Jan-05-24 07:00AM
Jan-04-24 07:00AM
Dec-21-23 07:00AM
Dec-20-23 07:00AM
Dec-14-23 07:00AM
Dec-01-23 01:32AM
Nov-27-23 07:00AM
Nov-13-23 07:00AM
Nov-02-23 07:00AM
10:44AM Loading…
Nov-01-23 10:44AM
Oct-31-23 07:53AM
07:27AM
06:30AM
06:30AM
Oct-25-23 03:42PM
09:00AM
Oct-22-23 10:30AM
Oct-20-23 05:01AM
Oct-19-23 07:00AM
Oct-16-23 07:00AM
Oct-10-23 07:00AM
Oct-03-23 09:45AM
Sep-28-23 06:00AM
Sep-27-23 07:00AM
Sep-26-23 07:00AM
Sep-25-23 07:00AM
Sep-23-23 09:00AM
Sep-19-23 02:00AM
Sep-18-23 07:32PM
10:14AM
Sep-08-23 11:35AM
Sep-06-23 12:04PM
Aug-28-23 07:32PM
01:03PM
10:47AM
07:00AM
Aug-24-23 07:00AM
Aug-21-23 01:05PM
Aug-18-23 07:32PM
Aug-15-23 07:00AM
Aug-14-23 07:00AM
Aug-08-23 12:36PM
07:12AM
06:30AM
06:30AM
Aug-05-23 09:49AM
Jul-28-23 05:14PM
Jul-13-23 07:00AM
Jul-10-23 07:00AM
Jun-22-23 02:55PM
12:57PM
08:00AM
08:00AM
07:38AM
07:38AM
Jun-16-23 11:23AM
Jun-01-23 07:00AM
May-29-23 06:47AM
May-25-23 07:00AM
May-18-23 07:00AM
May-16-23 10:45AM
07:00AM
May-12-23 09:07AM
May-10-23 07:00AM
May-03-23 06:30AM
06:30AM
May-02-23 07:00AM
06:40AM
Apr-19-23 07:22PM
Apr-17-23 07:00AM
Apr-13-23 07:00AM
Apr-12-23 07:00AM
Apr-11-23 06:24AM
Apr-05-23 07:00AM
Apr-03-23 07:00AM
Mar-31-23 10:36AM
Mar-27-23 06:45AM
Mar-17-23 07:15AM
07:00AM
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the Protein Sciences, and Diagnostics and Genomics segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Genomics segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nusse RoelandDirectorMar 07 '24Sale76.9810,400800,62743,097Mar 11 04:04 PM
Hippel JamesCFODec 19 '23Option Exercise31.2647,2891,478,254104,850Dec 21 04:06 PM
Nusse RoelandDirectorAug 30 '23Option Exercise22.4032,000716,80060,811Sep 01 04:06 PM
Nusse RoelandDirectorAug 30 '23Sale80.328,939717,95951,872Sep 01 04:06 PM
Kelderman KimPres. Diagnostics & GenomAug 24 '23Option Exercise47.602,10099,96021,225Aug 28 04:19 PM
Kummeth Charles R.Chief Executive OfficerAug 15 '23Option Exercise0.0017,63201,286,944Aug 17 04:14 PM
Kummeth Charles R.Chief Executive OfficerAug 05 '23Option Exercise0.0051,51601,310,282Aug 08 05:31 PM
Hippel JamesCFOAug 05 '23Option Exercise0.0012,876063,896Aug 08 05:29 PM
Kelderman KimPres. Diagnostics & GenomAug 05 '23Option Exercise0.008,060023,264Aug 08 05:28 PM
Kummeth Charles R.Chief Executive OfficerJul 21 '23Sale88.3680,0007,069,0241,258,766Jul 25 05:27 PM
Kummeth Charles R.Chief Executive OfficerJun 30 '23Option Exercise26.65616,67616,434,4151,729,493Jul 05 06:38 PM
Kummeth Charles R.Chief Executive OfficerJun 07 '23Sale83.0032226,7261,112,817Jun 09 04:07 PM
HIGGINS JOHN LDirectorApr 28 '23Option Exercise21.8516,000349,60039,360May 02 04:49 PM